Smart pillbox sends alerts to keep HIV treatment on track

NCT ID NCT06550804

NEW Ongoing Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial tests a smart pillbox that sends text alerts when a person misses their HIV medication. The alerts go to the user, a support person, and a case manager to help them get back on track. The study involves African American men who have sex with men and have trouble sticking to their antiretroviral therapy. The goal is to see if this approach is acceptable and feasible, and whether it improves medication adherence and viral suppression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A behavioral intervention using an electronic pillbox (Wisepill) that sends text alerts to the user, a support person, and a case manager when doses are missed.
What this could lead to: If effective, this approach could help people with HIV stay on their medication, achieve viral suppression, and reduce the risk of transmitting the virus.
What could go wrong: This is a pilot trial with a small number of participants, so results may not apply broadly. The intervention depends on consistent phone use and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHERENCE, MEDICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHERENCE, MEDICATION HIV INFECTIONS

Contacts and locations

Locations

University of Illinois Chicago

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.